Announcements Trials
Browse Landscape

Status

Available 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 12Observational 6Expanded_access 2

Sponsor

Cancer Type

Plasma cell 10Lymphoid 10Other hematologic neoplasm 5CNS 5Endocrine 2Thoracic 1Sarcoma 1Other neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Pheochromocytoma 7Neuroendocrine Tumors 7Paraganglioma 5Neuroblastoma 5Insulinoma 3Carcinoid Tumor 3Recurrence 2Neoplasms 2Hypoglycemia 2Hyperinsulinism 2Carcinoma, Medullary 2Adenoma, Islet Cell 2Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Liposarcoma 1Fibrosarcoma 1Congenital Hyperinsulinism 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Beckwith-Wiedemann Syndrome 1

Interventions

3-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Recurrence × Endocrine × Clear all
NCT03015844 2024-07-05

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Northwell Health

Available
CNSEndocrine

Neuroblastoma, Pheochromocytoma, Recurrence

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡